Headlines about Prothena (NASDAQ:PRTA) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prothena earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5292721679979 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern’s scoring:

PRTA has been the topic of several research analyst reports. Deutsche Bank reiterated a “buy” rating on shares of Prothena in a research report on Sunday, October 1st. Royal Bank of Canada reiterated a “buy” rating on shares of Prothena in a research report on Friday, September 29th. ValuEngine lowered shares of Prothena from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. SunTrust Banks reiterated a “buy” rating and issued a $75.00 target price on shares of Prothena in a research report on Monday, October 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $65.00 target price on shares of Prothena in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $75.58.

Prothena (PRTA) opened at $36.14 on Thursday. Prothena has a 52-week low of $34.85 and a 52-week high of $70.00.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.04. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. Prothena’s quarterly revenue was down 33.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.26) earnings per share. analysts predict that Prothena will post -4.27 earnings per share for the current year.

In related news, insider Tara Nickerson sold 17,500 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the transaction, the insider now directly owns 19,500 shares in the company, valued at $1,240,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $64.17, for a total transaction of $224,595.00. The disclosure for this sale can be found here. Insiders have sold 29,424 shares of company stock worth $1,922,787 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-prothena-prta-share-price/1775636.html.

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.